Q-omics provides the consensus-scored MIR548AT profile across patient tissues and cancer cell-line models. MIR548AT expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MIR548AT is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, MIR548AT RNA expression shows 11,358 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, LUAD, and THYM as cancer lineages where MIR548AT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR548AT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR548AT survival associations across molecular data types. MIR548AT RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR548AT RNA expression–survival associations across cancer types. High MIR548AT expression shows unfavorable associations in KICH, LUSC, KIRC, UVM, THYM and DLBC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MIR548AT RNA expression.
This table summarizes MIR548AT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR548AT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR548AT shows higher tumor expression in LUAD, KIRC and CHOL. The LUAD box plot shows higher MIR548AT RNA expression in tumor versus normal tissue (log2 FC = +0.874, t-test p = .008).
This table shows molecular features associated with MIR548AT in patient tissues and cancer cell lines. In patient samples, MIR548AT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
